JP Morgan Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $70
JP Morgan analyst Jessica Fye maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $76 to $70.
Share
Why It Matters
A big bank expert still likes Ionis overall, but thinks the stock might be worth less money. This shows the company is doing okay, even if the expert slightly lowered their price guess.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.